Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04886063 · ClinicalTrials.gov registry record · Phase 2
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by LeonaBio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 423
- Enrollment target
NCT04886063 is a Phase 2 study that was terminated before completion, run by LeonaBio. The registered enrollment target is 423 participants.
The verdict
NCT04886063, a Phase 2 study, was terminated before completion, sponsored by LeonaBio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 423 participants
- Enrollment target
Study Summary
The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202.
Interventions
- DRUG ATH-1017
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04886063
The ClinicalTrials.gov registry entry for NCT04886063 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 423 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LeonaBio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ATH-1017 is the first listed.
NCT04886063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04886063 about?
NCT04886063 is a clinical study titled "Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease". The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's disease who completed the 26-week randomized treatment in Study ATH-1017-AD-0201 or Study ATH-1017-AD-0202.
What is the current status of trial NCT04886063?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 423 participants. The study started on 2021-06-30. Estimated completion is 2024-10-23.
What interventions are being tested in trial NCT04886063?
The interventions under investigation include: ATH-1017 (DRUG).
Who is sponsoring clinical trial NCT04886063?
This trial is sponsored by LeonaBio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.